バイオアトラに関するコメント

$バイオアトラ (BCAB.US)$  ya some gemoks like to short theirs off

$バイオアトラ (BCAB.US)$
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown ...

$バイオアトラ (BCAB.US)$ well well well good shorts

$バイオアトラ (BCAB.US)$ any advice to hold or to sell???

$バイオアトラ (BCAB.US)$
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Mee...

Scion Asset Management (AUM: $52M)
*Buys: $シフト4・ペイメント (FOUR.US)$ , $モリーナ・ヘルスケア (MOH.US)$ , $ハドソン・パシフィック・プロパティーズ (HPP.US)$ , $オラプレックス・ホールディングス (OLPX.US)$ , $バイオアトラ (BCAB.US)$
*Adds: $バイドゥ (BIDU.US)$ , $アリババ・グループ (BABA.US)$
*Reduced: $JDドットコム (JD.US)$ , $リアルリアル (REAL.US)$
*Sold: $HCAヘルスケア (HCA.US)$ , $シティグループ (C.US)$ $Sprott Physical Gold Trust (PHYS.US)$ , $ブロック (SQ.US)$ , $ザ・シグナ・グループ (CI.US)$ , $アドバンス･オート･パーツ (AAP.US)$ , $ビーピー (BP.US)$ , ...

$イミュニリング・コープ (IMRX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $iシェアーズ バイオテクノロジー ETF (IBB.US)$ $S&P 500 Index (.SPX.US)$ $バイオアトラ (BCAB.US)$ $ギリアド・サイエンシズ (GILD.US)$ $アフィメド (AFMD.US)$ $インスティル・バイオ (TIL.US)$ $ヌカルタ (NKTX.US)$
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...

$バイオアトラ (BCAB.US)$ Reuters· just
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

$バイオアトラ (BCAB.US)$ Reuters· 2 mins ago
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3361, a Cab-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors